Program
paliperidone
Also written as “Paliperidone ER”, “Paliperidone” and “Paliperidone palmitate”.
Its studies are mostly in Schizophrenia · Psychotic Disorders · Bipolar Disorder · Psychomotor Agitation, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 1000 open or running | phase 4since Aug 30, 2007 | Nov 19, 2003 | none ahead |
| Luye Pharma Group | 30 open or running | phase 1since May 8, 2020 | May 8, 2020 | none ahead |
| CSPC Pharmaceutical Group | 21 open or running | no phasesince Sep 30, 2025 | Sep 30, 2025 | Dec 31, 2026NCT07493551 |
| Pharmathen | 10 open or running | phase 2since Jan 26, 2018 | Jan 26, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Nov 20, 2008.
- Apr 28, 2015Phase 3 study in SchizophreniaJohnson & Johnson · NCT02431702 · 337 enrolled · United States, Brazil, Mexico
- Jun 2, 2015Phase 2 study in SchizophreniaJohnson & Johnson · NCT02462473 · 9 enrolled · United States
- Nov 2, 2015Phase 1 study in ImmunoassayJohnson & Johnson · NCT02634463 · 81 enrolled · Belgium
- Mar 15, 2016Phase 3 study in SchizophreniaJohnson & Johnson · NCT02713282 · 306 enrolled · Croatia, Denmark, France and more
- Nov 14, 2017Phase 3 study in SchizophreniaJohnson & Johnson · NCT03345342 · 841 enrolled · United States, Argentina, Australia and more
- Jan 26, 2018Pharmathen's first study: phase 2 study in SchizophreniaNew to PharmathenPharmathen · NCT03425552 · 70 enrolled · Jordan
- Oct 18, 2018Phase 4 study in SchizophreniaJohnson & Johnson · NCT03713658 · 34 enrolled · Rwanda
- Aug 16, 2019Phase 3 study in SchizophreniaJohnson & Johnson · NCT04072575 · 178 enrolled · Argentina, Hong Kong, Italy and more
- May 8, 2020Luye Pharma Group's first study: phase 1 study in Schizophrenia PatientsNew to Luye Pharma GroupLuye Pharma Group · NCT04572685 · 36 enrolled · United States
- Apr 27, 2021Phase 1 study in SchizophreniaLuye Pharma Group · NCT04922593 · 281 enrolled · United States
- Jun 22, 2021Phase 4 study in SchizophreniaJohnson & Johnson · NCT04940039 · 93 enrolled · Rwanda
- Dec 6, 2021Phase 1 study in SchizophreniaLuye Pharma Group · NCT05321602 · 89 enrolled · United States
- Sep 30, 2025CSPC Pharmaceutical Group's first study: no phase study in SchizophreniaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07268430 · 256 enrolled · China
- Mar 4, 2026No phase study in SchizophreniaCSPC Pharmaceutical Group · NCT07493551 · 260 planned · China
Ahead
- Dec 31, 2026Primary completion: no phase study in SchizophreniaCSPC Pharmaceutical Group · NCT07493551
TargetBeta
“Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| lurasidonerule | Sumitomo Pharma | phase 4 | 52 |
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 15 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
Studies
The newest 60 of 106 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07493551Schizophrenia · China | – | Recruiting | CSPC Pharmaceutical Group | Dec 31, 2026 | 260 |
| NCT07268430Schizophrenia · China | – | Completed | CSPC Pharmaceutical Group | Dec 25, 2024 | 256 |
| NCT05321602Schizophrenia · United States | 1 | Completed | Luye Pharma Group | Sep 23, 2022 | 89 |
| NCT04940039Schizophrenia · Rwanda | 4 | Completed | Johnson & Johnson | Apr 16, 2024 | 93 |
| NCT04922593Schizophrenia · United States | 1 | Completed | Luye Pharma Group | Mar 15, 2022 | 281 |
| NCT04572685Schizophrenia Patients · United States | 1 | Completed | Luye Pharma Group | Jun 26, 2020 | 36 |
| NCT04072575Schizophrenia · Argentina, Hong Kong, Italy and more | 3 | Completed | Johnson & Johnson | May 3, 2022 | 178 |
| NCT03713658Schizophrenia · Rwanda | 4 | Completed | Johnson & Johnson | Dec 2, 2019 | 34 |
| NCT03425552Schizophrenia · Jordan | 2 | Completed | Pharmathen | May 2, 2019 | 70 |
| NCT03345342Schizophrenia · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | May 8, 2020 | 841 |
| NCT02713282Schizophrenia · Croatia, Denmark, France and more | 3 | Completed | Johnson & Johnson | Mar 26, 2018 | 306 |
| NCT02634463Immunoassay · Belgium | 1 | Completed | Johnson & Johnson | Nov 9, 2016 | 81 |
| NCT02462473Schizophrenia · United States | 2 | Terminated | Johnson & Johnson | Jan 2016 | 9 |
| NCT02431702Schizophrenia · United States, Brazil, Mexico | 3 | Completed | Johnson & Johnson | Nov 12, 2019 | 337 |
| NCT02087579Psychotic Disorders · United States, Argentina, Belgium and more | 1 | Completed | Johnson & Johnson | Oct 2014 | 305 |
| NCT01947803Schizophrenia · China | 4 | Completed | Johnson & Johnson | Mar 2015 | 353 |
| NCT01942382Schizophrenia | 1 | Completed | Johnson & Johnson | Mar 2010 | 76 |
| NCT01724359Schizophrenia · Argentina, Colombia | 4 | Completed | Johnson & Johnson | Nov 2009 | 95 |
| NCT01685931Schizophrenia · China | 4 | Completed | Johnson & Johnson | Dec 2014 | 617 |
| NCT01682161Schizophrenia · Korea, Republic of | 4 | Completed | Johnson & Johnson | Sep 2013 | 154 |
| NCT01670071Schizophrenia · Taiwan | 4 | Terminated | Johnson & Johnson | Jun 2015 | 17 |
| NCT01662648Schizophrenia | 3 | Completed | Johnson & Johnson | Apr 2008 | 1,117 |
| NCT01607762Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 2012 | 31 |
| NCT01606228Schizophrenia | 3 | Completed | Johnson & Johnson | Dec 2008 | 188 |
| NCT01606254Schizophrenia · Japan | 2 | Completed | Johnson & Johnson | Apr 2008 | 56 |
| NCT01577186Schizophrenia | 4 | Completed | Johnson & Johnson | Jun 2009 | 480 |
| NCT01577160Schizophrenia | 4 | Completed | Johnson & Johnson | Apr 2009 | 353 |
| NCT01662310Schizophrenia · China | 3 | Completed | Johnson & Johnson | Apr 2013 | 201 |
| NCT01561898Schizophrenia | 3 | Completed | Johnson & Johnson | Oct 2008 | 228 |
| NCT01541371Schizophrenia | 3 | Completed | Johnson & Johnson | Sep 2009 | 405 |
| NCT01529515Schizophrenia · United States, Colombia, Malaysia and more | 3 | Completed | Johnson & Johnson | Apr 2014 | 509 |
| NCT01527305Schizophrenia · China, Korea, Republic of, Malaysia and more | 4 | Completed | Johnson & Johnson | Dec 31, 2013 | 212 |
| NCT01515423Schizophrenia · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Feb 2015 | 1,429 |
| NCT01448720Schizophrenia · Brazil, Colombia, Mexico | 3 | Completed | Johnson & Johnson | Dec 2013 | 142 |
| NCT01387542Schizophrenia · Thailand | 4 | Completed | Johnson & Johnson | Sep 2010 | 40 |
| NCT01362439Schizophrenia | 4 | Completed | Johnson & Johnson | Mar 2010 | 133 |
| NCT01299389Schizophrenia · Japan, Korea, Republic of, Taiwan | 3 | Completed | Johnson & Johnson | May 2012 | 323 |
| NCT01281527Schizophrenia · Austria, Belgium, Croatia and more | 3 | Completed | Johnson & Johnson | Nov 2012 | 1,044 |
| NCT01258920Schizophrenia · Japan | 3 | Completed | Johnson & Johnson | Nov 2012 | 201 |
| NCT01193166Schizophrenia | 4 | Withdrawn | Johnson & Johnson | Sep 2012 | 0 |
| NCT01193153Psychotic Disorders · United States, Bulgaria, India and more | 3 | Completed | Johnson & Johnson | Oct 2013 | 667 |
| NCT01150448Schizophrenia · United States, Belgium, Croatia and more | 1 | Completed | Johnson & Johnson | Jun 2009 | 212 |
| NCT01157351Schizophrenia · United States, Puerto Rico | 4 | Completed | Johnson & Johnson | Dec 2013 | 450 |
| NCT01110317Schizophrenia | 1 | Completed | Johnson & Johnson | 49 | |
| NCT01081769Schizophrenia · Austria, Belgium, Bulgaria and more | 3 | Completed | Johnson & Johnson | Feb 2013 | 769 |
| NCT01094249Schizophrenia · United States | 1 | Completed | Johnson & Johnson | Apr 2009 | 9 |
| NCT01060228Schizophrenia | 1 | Completed | Johnson & Johnson | 24 | |
| NCT01050478Psychomotor Agitation · Belgium | 4 | Completed | Johnson & Johnson | Dec 2011 | 56 |
| NCT01051531Schizophrenia · Australia, China, Hong Kong and more | 3 | Completed | Johnson & Johnson | May 17, 2013 | 546 |
| NCT01010776Schizophrenia · Brazil | 4 | Completed | Johnson & Johnson | Dec 2009 | 223 |
| NCT01009047Schizophrenia · United States, India, Romania and more | 3 | Completed | Johnson & Johnson | Jun 2012 | 228 |
| NCT00934635Schizophrenia · Germany | 4 | Terminated | Johnson & Johnson | Dec 2009 | 2 |
| NCT00946985Schizophrenia · United States, Brazil, Bulgaria and more | 4 | Terminated | Johnson & Johnson | Mar 2010 | 163 |
| NCT00915512Schizophrenia · Turkey | 4 | Completed | Johnson & Johnson | Oct 2011 | 84 |
| NCT00892489Schizophrenia | 1 | Completed | Johnson & Johnson | 80 | |
| NCT00892541Schizophrenia | 1 | Completed | Johnson & Johnson | 30 | |
| NCT00892320Schizophrenia | 1 | Completed | Johnson & Johnson | 20 | |
| NCT00796835Schizophrenia | 1 | Completed | Johnson & Johnson | 50 | |
| NCT00796471Schizophrenia | 1 | Completed | Johnson & Johnson | 35 | |
| NCT00796185Schizophrenia | 1 | Completed | Johnson & Johnson | 62 |
How it is read
Names in the registry
- “Paliperidone ER”, 39 entries
- “Paliperidone”, 13 entries
- “Paliperidone palmitate”, 10 entries
- “paliperidone palmitate”, 7 entries
- “Paliperidone Palmitate”, 6 entries
Conditions, from the studies’ own filings
- Schizophrenia, 95 studies
- Psychotic Disorders, 4 studies
- Bipolar Disorder, 4 studies
- Psychomotor Agitation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.